Stocksigma LogoStocksigma Logo

Mahamaya Lifesciences Reports Strong H1 FY27 Financial Performance

Mahamaya Lifesciences posted robust results for the half year ended 30th Sep'26, with consolidated revenue from operations rising 29.78% YoY to ₹21,162.92

Mahamaya Lifesciences Reports Strong H1 FY27 Financial Performance

Mahamaya Lifesciences Ltd · Financial Result · 13 Nov 2026, 6:57 pm

Mahamaya Lifesciences Reports Strong H1 FY27 Financial Performance Mahamaya Lifesciences posted robust results for the half year ended 30th Sep'26, with consolidated revenue from operations rising 29.78% YoY to ₹21,162.92 lakhs compared to ₹16,306.37 lakhs in the previous year. Consolidated Profit Before Tax grew 36.18% YoY to ₹1,554.18 lakhs, while Profit After Tax expanded 38.00% YoY to ₹1,154.87 lakhs, delivering a Basic EPS of ₹4.93. Operating cash flows improved significantly to ₹932.58 lakhs. Out of ₹61.96 crore in IPO proceeds, the company has deployed ₹32.72 crore, leaving ₹29.24 crore unutilized in deposits and monitoring accounts.

Original exchange filing (PDF)

More announcements from Mahamaya Lifesciences Ltd

All Mahamaya Lifesciences Ltd announcements